Cantor Fitzgerald Initiates Overweight Rating on Lexicon Pharmaceuticals Amid Optimism for Inpefa's Phase 3 Data
Cantor Fitzgerald has initiated an overweight rating on Lexicon Pharmaceuticals (LXRX), citing optimism around the upcoming phase 3 data for its drug candidate, sotagliflozin (Inpefa). The SGLT1/2 inhibitor is being evaluated as a treatment for hypertrophic cardiomyopathy. Positive results are expected in Q1 2027 and could significantly impact Lexicon's stock performance. The firm’s positive outlook reflects confidence that Inpefa may demonstrate efficacy beyond its current indications, potentially expanding the drug’s market application into cardiovascular disease management. This development is seen as a key catalyst for near-term investor interest.
Topics: Clinical Trials Hypertrophic Cardiomyopathy (HCM) Pharmaceuticals SGLT1/2 Inhibitors